A detailed history of Payden & Rygel transactions in Merck & Co., Inc. stock. As of the latest transaction made, Payden & Rygel holds 185,150 shares of MRK stock, worth $18.2 Million. This represents 1.62% of its overall portfolio holdings.

Number of Shares
185,150
Previous 120,150 54.1%
Holding current value
$18.2 Million
Previous $14.9 Million 41.35%
% of portfolio
1.62%
Previous 1.2%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$111.15 - $128.97 $7.22 Million - $8.38 Million
65,000 Added 54.1%
185,150 $21 Million
Q2 2024

Oct 07, 2024

SELL
$123.8 - $132.96 $5.78 Million - $6.21 Million
-46,700 Reduced 27.99%
120,150 $14.9 Million
Q1 2024

Oct 08, 2024

BUY
$113.24 - $131.95 $1.31 Million - $1.53 Million
11,600 Added 9.65%
131,750 $17.4 Million
Q4 2023

Feb 12, 2024

SELL
$100.18 - $109.02 $2.92 Million - $3.17 Million
-29,100 Reduced 14.85%
166,850 $18.2 Million
Q2 2023

Aug 10, 2023

SELL
$108.61 - $118.38 $4.76 Million - $5.19 Million
-43,850 Reduced 18.29%
195,950 $22.6 Million
Q1 2023

May 10, 2023

SELL
$102.94 - $114.86 $10.1 Million - $11.3 Million
-98,210 Reduced 29.06%
239,800 $25.5 Million
Q4 2022

Feb 13, 2023

SELL
$87.44 - $112.11 $5.79 Million - $7.42 Million
-66,200 Reduced 16.38%
338,010 $37.5 Million
Q3 2022

Nov 10, 2022

BUY
$84.53 - $94.96 $18.3 Million - $20.6 Million
216,800 Added 115.68%
404,210 $34.8 Million
Q2 2022

Aug 12, 2022

BUY
$83.49 - $94.64 $15.4 Million - $17.4 Million
184,000 Added 5395.89%
187,410 $17.1 Million
Q4 2021

Feb 11, 2022

SELL
$72.28 - $90.54 $34.5 Million - $43.2 Million
-477,100 Reduced 99.29%
3,410 $261,000
Q3 2021

Nov 15, 2021

BUY
$71.68 - $78.83 $4.22 Million - $4.64 Million
58,900 Added 13.97%
480,510 $36.1 Million
Q2 2021

Aug 06, 2021

SELL
$70.31 - $77.77 $154,682 - $171,094
-2,200 Reduced 0.52%
421,610 $32.8 Million
Q1 2021

May 13, 2021

BUY
$68.86 - $81.11 $8.75 Million - $10.3 Million
127,100 Added 42.84%
423,810 $32.7 Million
Q4 2020

Feb 08, 2021

SELL
$71.77 - $79.65 $10.2 Million - $11.3 Million
-142,100 Reduced 32.38%
296,710 $24.3 Million
Q3 2020

Nov 10, 2020

BUY
$73.18 - $82.95 $1.42 Million - $1.61 Million
19,400 Added 4.63%
438,810 $36.4 Million
Q2 2020

Aug 12, 2020

SELL
$70.42 - $80.13 $10.2 Million - $11.6 Million
-145,090 Reduced 25.7%
419,410 $32.4 Million
Q1 2020

May 04, 2020

BUY
$63.36 - $87.82 $3.16 Million - $4.38 Million
49,920 Added 9.7%
564,500 $43.4 Million
Q4 2019

Jan 31, 2020

SELL
$77.58 - $87.54 $178,434 - $201,342
-2,300 Reduced 0.44%
514,580 $46.8 Million
Q3 2019

Oct 30, 2019

BUY
$76.08 - $82.93 $1.17 Million - $1.28 Million
15,380 Added 3.07%
516,880 $43.5 Million
Q2 2019

Aug 06, 2019

BUY
$69.84 - $81.59 $1.02 Million - $1.19 Million
14,600 Added 3.0%
501,500 $42.1 Million
Q4 2018

Jan 25, 2019

BUY
$65.24 - $75.71 $711,116 - $825,238
10,900 Added 2.29%
486,900 $37.2 Million
Q3 2018

Nov 07, 2018

SELL
$57.69 - $67.84 $2.11 Million - $2.48 Million
-36,500 Reduced 7.12%
476,000 $33.8 Million
Q1 2018

May 09, 2018

BUY
$50.96 - $59.23 $8.19 Million - $9.52 Million
160,800 Added 45.72%
512,500 $27.9 Million
Q3 2017

Nov 14, 2017

BUY
$58.67 - $63.13 $20.6 Million - $22.2 Million
351,700
351,700 $22.5 Million

Others Institutions Holding MRK

About Merck & Co., Inc.


  • Ticker MRK
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,533,280,000
  • Market Cap $249B
  • Description
  • Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, ...
More about MRK
Track This Portfolio

Track Payden & Rygel Portfolio

Follow Payden & Rygel and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Payden & Rygel, based on Form 13F filings with the SEC.

News

Stay updated on Payden & Rygel with notifications on news.